- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colonic Neoplasms, Colorectal Neoplasms
- Interventions
- GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
- Drug
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • New York, New York • Cincinnati, Ohio
- Conditions
- Cancer
- Interventions
- GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Sarasota, Florida + 1 more
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
- Interventions
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
- Device · Drug
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced/Metastatic Solid Tumor
- Interventions
- KZR-261
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
- Conditions
- Pancreatic Cancer
- Interventions
- ABTL0812, Folfirinox, Placebo
- Drug
- Lead sponsor
- Ability Pharmaceuticals SL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
- Conditions
- Vascular; Lesion, Central Nervous System, Brain Tumor, Cerebral Aneurysm, Cerebral AVM
- Interventions
- GLOW800, indocyanine green (ICG)
- Device · Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
- Conditions
- Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
- Drug · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Back Pain
- Interventions
- TransDiscal System, Medical Management
- Device · Other
- Lead sponsor
- Halyard Health
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Washington D.C., District of Columbia • Orlando, Florida • Bloomington, Illinois + 6 more
- Conditions
- Prostate Cancer
- Interventions
- External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI)
- Radiation · Drug · Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hepatic Impairment
- Interventions
- Radiprodil
- Drug
- Lead sponsor
- GRIN Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- DeSoto, Texas • San Antonio, Texas
- Conditions
- Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
- Interventions
- Suzetrigine, Acetaminophen, oxycodone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Cancer
- Interventions
- Custirsen, paclitaxel and carboplatin
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 1 more
- Conditions
- Complication of Transplanted Lung
- Interventions
- Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant
- Drug · Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Durham, North Carolina
- Conditions
- Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
- Interventions
- Cefiderocol, Best Available Therapy
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
- Conditions
- Coronary Artery Disease
- Interventions
- PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Loveland, Colorado • Petoskey, Michigan
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1305/BNT325, Pembrolizumab, BNT327
- Drug · Combination Product
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 42
- States / cities
- Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
- Conditions
- Shock
- Interventions
- Norepinephrine, Epinephrine, Phenylephrine, Vasopressin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 836 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Congenital Heart Disease
- Interventions
- Digoxin
- Drug
- Lead sponsor
- Christoph P Hornik, MD MPH
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 50 participants
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 8 more
- Conditions
- Healthy
- Interventions
- tofacitinib modified-release (MR) formulation
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
- Drug
- Lead sponsor
- Adagene Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Necrotizing Enterocolitis
- Interventions
- ST266
- Biological
- Lead sponsor
- Noveome Biotherapeutics, formerly Stemnion
- Industry
- Eligibility
- 2 Weeks to 8 Weeks
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more